Faculty Profiles - WATANABE Toyohiko

Papers - WATANABE Toyohiko

Division display 381 - 400 of about 429 ／ All the affair displays >>

泌尿器科領域におけるbalofloxacinの基礎的・臨床的検討

竹中皇, 藤田竜二, 渡辺豊彦

日本化学療法学会雑誌 43 ( Suppl.5 ) 324 - 329 1995.11

Language：Japanese Publisher：(公社)日本化学療法学会

1)教室保存株14菌種210株に対する本剤のMICを測定し,OFLX及びNFLXの抗菌力と比較した.本剤のグラム陽性菌に対する抗菌力は比較対照薬剤に比し優れており,グラム陰性菌に対しては全体としてOFLXには若干劣るものの,NFLXとほぼ同等の抗菌力を示した. 2)急性単純性膀胱炎4例,複雑性尿路感染症6例及び急性細菌性前立腺炎1例に対し,8日間投与し,臨床的検討を行った.急性単純性膀胱炎例では判定可能であった3例の内2例が著効,1例が有効であった.複雑性尿路感染症では著効3例,有効1例,無効1例であった.急性細菌性前立腺炎の1例では有効であった.複雑性UTIにおける細菌学的効果では12株中11株が消失した. 3)自他覚的副作用は1例も認めず,臨床検査値異常変動もなかった

泌尿器科領域におけるpazufloxacinの基礎的・臨床的検討

渡辺豊彦, 竹中皇, 櫻本耕司

日本化学療法学会雑誌 43 ( Suppl.2 ) 363 - 376 1995.9

Language：Japanese Publisher：(公社)日本化学療法学会

1)尿路感染症由来株14菌種207株に対するPZFXのMICを測定し,norfloxacin(NFLX), ofloxacin(OFLX)と比較検討した.グラム陽性菌に対しては,OFLXとほぼ同等,グラム陰性菌に対しては,殆どの菌種に対して対照薬より優れた抗菌力を示した.P.aeruginosaに対する本剤及び対照薬の抗菌力は年次的に耐性化傾向が認められた. 2)急性単純性膀胱炎2例,複雑性尿路感染症19例,急性前立腺炎1例,及び慢性前立腺炎3例を対象にした.急性単純性膀胱炎2例では,主治医判定で共に有効以上であった.複雑性尿路感染症17例では,総合臨床効果は,著効7例,有効5例,無効5例で有効率71%であった

Drug Sensitivity and Expression of β-lactamase in Enterococci Isolated at Okayama University Hospital Reviewed

NASU Yoshitsugu, WATANABE Toyohiko, MONDEN Koichi, SAKURAMOTO Koushi, ONO Akinori, TSUGAWA Masaya, KUMON Hiromi, OHMORI Hiroyuki, YASUI Terue

Journal of the Japanese Association for Infectious Diseases 69 ( 8 ) 919 - 923 1995.8

Language：Japanese Publisher：The Japanese Association for Infectious Diseases

The following results were obtained from a study of Enterococci isolated at the Okayama University Hospital from 1990 to 1994.<BR>1) The isolation frequency of Enterococci was about 6% for each year.<BR>2) The percentage of Enterococcus faecalis (E. faecalis) among Enterococci decreased each year, but the percentage of Enterococcus faecium (E. faecium) , and Enterococcus avium (E. avium) increased each year.<BR>3) Results of drug sensitivity tests revealed that the incidence of ofloxacin (OFLX) resistant E. faecalis and E. avium increased each year. Also, the resistance of E. faecalis to ampicillin (ABPC), the primary medication choice for treating E. faecalis, increased each year.<BR>4) A few vancomycin (VCM) non-sensitive Enterococci were isolated. These bacteria showed low-sensitivity toward ABPC, imipenem (IPM), gentamicin (GM), and OFLX, and the extent of multiple drug resistance increased each year.<BR>5) One hundred strains of Enterococci were selected to examine the expression of β-lactamase using the broth method and the iodine-starch method. However, β-lactamase producing strains were not detected.

DOI： 10.11150/kansenshogakuzasshi1970.69.919

Grepafloxacinの泌尿器科領域における基礎的・臨床的検討

竹中皇, 渡辺豊彦, 櫻本耕司

日本化学療法学会雑誌 43 ( Suppl.1 ) 397 - 404 1995.7

Language：Japanese Publisher：(公社)日本化学療法学会

1) 尿路感染症由来菌14菌種210株に対する本剤のMICを測定し,同系薬剤であるofloxacin(OFLX), ciprofloxacin(CPFX)およびnorfloxacin(NFLX)と比較した.全体として,CPFXに劣るものの,その他の同系薬剤とほぼ同等あるいはそれ以上の抗菌力を示した.2) 急性単純性膀胱炎4例,複雑性尿路感染症28例および急性細菌性前立腺炎2例に対し,本剤を1回量100〜300mg,1日1〜2回,1〜14日間投与し,UTI薬効評価基準に準じて臨床的検討を行った.急性単純性膀胱炎4例,急性細菌性前立腺炎1例に対してはどちらも有効以上であったが,複雑性尿路感染症に対しては著効5例,有効3例,無効14例であった.細菌学的効果では25株中15株が消失した.自・他覚的副作用は1例に一過性の左半身不快感を認め,臨床検査値異常では軽度の好酸球増多,GOT・GPTの上昇を各1例に認めた

Robbins deviceを用いた緑膿菌バイオフィルムの解析緑膿菌バイオフィルムに対する各種抗菌剤の効果について

小野憲昭, 渡辺豊彦, 竹中皇

BACTERIAL ADHERENCE研究会講演録 8 95 - 100 1995.4

Language：Japanese Publisher：日本バイオフィルム学会

Robbins deviceをバイオフィルム・サンプラーとして用い,緑膿菌バイオフィルムで抗菌剤の効果を,ホタル・ルシフェリン・ルシフェラーゼ反応によるchemiluminescence法で測定し,更に電子顕微鏡で検討した.キノロン剤とfosfomycin(FOM)が人工尿中でも併用効果を挙げた.またレーザー走査電子顕微鏡は表層と深層での細胞密度の差を形態的に判定可能であった

共焦点レーザー走査顕微鏡による細菌バイオフィルムの観察 P.aeruginosa biofilmとS.epidermidis biofilmの比較

渡辺豊彦, 竹中皇, 櫻本耕司

BACTERIAL ADHERENCE研究会講演録 8 89 - 94 1995.4

Language：Japanese Publisher：日本バイオフィルム学会

新しい共焦点レーザー走査電子顕微鏡でP.aeruginosa biofilmとS.epidermidis biofilmの蛍光染色性を比較した.ともに生の状態での生物資料の観察が可能であり,前者ではsafranineとFITC-ConAで識別可能であった.後者ではsafranineの二重染色は不能で,前者と共に単染色ではacridine orangeとFITC-ConAが現時点では最も優れた染色性を示した

難治性複雑性尿路感染症に対するazithromycinとofloxacinの併用効果に関する検討 Reviewed

小野憲昭, 渡辺豊彦, 竹中皇

日本化学療法学会雑誌 43 ( 2 ) 222 - 230 1995.2

Language：Japanese Publisher：(公社)日本化学療法学会

カテーテル留置難治性複雑性尿路感染症に対し,AZMとOFLXの併用療法は有効な方法のひとつであると考えられ,また安全性にも問題は認められず,尿路のバイオフィルム感染症に対する治療法全般を検討していくうえでも意義深いものであると考えられた

尿路感染症に対するritipenem acoxilの基礎的・臨床的検討

小野憲昭, 藤田竜二, 渡辺豊彦

日本化学療法学会雑誌 43 ( Suppl.3 ) 256 - 263 1995.1

Language：Japanese Publisher：(公社)日本化学療法学会

1)尿路感染症由来の14菌種210株に対するritipenem(RIPM)のMICを測定し,cefaclor(CCL), cefixime(CFIX), cefotiam(CTM)と比較検討した.グラム陽性菌,特にEnterococcus faecalisでは対照薬剤より優れた抗菌力を示した.グラム陰性菌に対してはCFIX, CTMよりやや劣るものの,CCLより優れた抗菌力を示した. 2)34例の尿路感染症患者(急性単純性膀胱炎4例, 複雑性尿路感染症30例)を対象に,本剤1日量450mg〜1500mgを1日3回,3〜14日間食後投与し,UTI薬効評価基準に基づき判定した.急性単純性膀胱炎では2例が効果判定可能で,著効1例,有効1例であった.複雑性尿路感染症では,著効6例,有効18例,無効4例であった

Ritipenem acoxilの体内動態の検討 Cefotiam hexetilとの比較

小野憲昭, 藤田竜二, 渡辺豊彦

日本化学療法学会雑誌 43 ( Suppl.3 ) 286 - 291 1995.1

Language：Japanese Publisher：(公社)日本化学療法学会

健常成人男子ボランティアにRIPM-AC,CTM-HEともに200mg錠を単回投与し,クロスオーバー法で各薬剤の血漿中濃度,及び尿中排泄を検討した.最高血漿中濃度(Cmax)は,ritipenem(RIPM)では2.09μg/ml, cefotiam(CTM)では2.85μg/mlを示した.RIPM, CTMの血漿中濃度半減期(T1/2)は,それぞれ0.56h, 0.71h, 12時間までの血漿中濃度曲線下面積(AUC0-12)はそれぞれ2.10μg・h/ml, 4.99μg・h/ml.活性体の累積尿中排泄率は12時間までで,RIPM11.3%, CTM38.9%であった

Basic and clinical studies on grepafloxacin in the urological fiel Reviewed

Tadasu Takenaka, Toyohiko Watanabe, Kohji Sakuramoto, Toshihide Hayashi, Kazuhiro Hata, Noriaki Ono, Hiromi Kumon, Hiroyuki Ohmori, Yasuhiro Katayama, Akihiro Mizuno, Mikio Kishi, Ryoji Nasu

Japanese Journal of Chemotherapy 43 397 - 404 1995

Language：English Publishing type：Research paper (scientific journal)

We studied the antibacterial activity and clinical usefulness of grepafloxacin (GPFX), a new quinolone, in the urological field. 1) Antibacterial activity: The MICs of GPFX were measured against 210 clinical isolates of 14 species from urinary tract infection and compared with those of ofloxacin (OFLX), ciprofloxacin (CPFX) and norfloxacin (NFLX). In general, the antibacterial activity of GPFX was inferior to CPFX, but equal or superior to those of other control drugs. 2) Clinical efficacy: Although the clinical efficacy in acute uncomplicated cystitis and chronic bacterial prostatitis was good, the overall clinical efficacy rate according to the criteria of the UTI Committee was 36.4%(8/22) in chronic complicated UTI. Fifteen of 25 (60%) strains isolated were eradicated. 3) Side effects: Temporary discomfort of the left side of the body was observed in one case. Mild elevation of eosinophils or GOT·GPT was observed in one case. © 1995, Japanese Society of Chemotherapy. All rights reserved.

DOI： 10.11250/chemotherapy1995.43.Supplement1_397

Pharmacokinetics of ritipenem acoxil Reviewed

Noriaki Ono, Ryuji Fujita, Toyohiko Watanabe, Tadasu Takenaka, Kouichi Monden, Satoshi Uno, Koushi Sakuramoto, Toshihide Hayashi, Kazuhiro Hata, Yoshitsugu Nasu, Masaya Tsugawa, Hiromi Kumon, Hiroyuki Ohmori, Shin Irie, Tetsuzo Kaneshige

Japanese Journal of Chemotherapy 43 286 - 291 1995

Language：English Publishing type：Research paper (scientific journal)

Ritipenem acoxil (RIPM-AC) is a new oral penem antibiotic. We investigated the pharmacokinetics of RIPM-AC and cefotiam hexetil (CTM-HE) by the cross-over method. The pharmacokinetics of RIPM-AC and CTM-HE, each orally administrated at a dose of 200 mg, were compared in healthy male volunteers. The Cmax values of ritipenem (RIPM) and cefotiam (CTM) were 2.09μgg/ml and 2.85μg/ml, respectively. The T1/2 of RIPM and CTM were 0.56 h and 0.71 h, and the AUC0-12 values were 2.10 μg·h/ml and 4.99 μg·h/ml. The mean urinary recovery rates of RIPM and CTM up to 12 h after a single oral administration were 11.3% and 38.9%. © 1995, Japanese Society of Chemotherapy. All rights reserved.

DOI： 10.11250/chemotherapy1995.43.Supplement3_286

Basic and clinical studies on ritipenem acoxil in urinary tract infection Reviewed

Noriaki Ono, Ryuuji Fujita, Toyohiko Watanabe, Tadasu Takenaka, Kouichi Monden, Koushi Sakuramoto, Toshihide Hayashi, Kazuhiro Hata, Yoshitsugu Nasu, Masaya Tsugawa, Hiromi Kumon, Hiroyuki Ohmori, Katsuichi Nanba, Katsuyoshi Kondo, Teruhisa Ohhashi, Teruaki Akaeda, Yasuhiro Katayama

Japanese Journal of Chemotherapy 43 256 - 263 1995

Language：English Publishing type：Research paper (scientific journal)

We studied the antibacterial activity and clinical efficacy of ritipenem acoxil (RIPM-AC), a neworal penem antibiotic, in urinary tract infections. 1) Antibacterial activity: We measured the MICs of ritipenem (RIPM) against 210 clinicalisolates of 14 species from urinary tract infections and compared them with those of cefaclor (CCL), cefixime (CFIX) and cefotiam (CTM). Against gram-positive organisms, the overallantibacterial activity of RIPM was superior to that of other antibiotics. Against gram-negativeorganisms, the activity of RIPM was almost equivalent to that of other antibiotics. 2) Clinical efficacy: Four patients with acute uncomplicated cystitis (AUC) and 30 patients withchronic complicated urinary tract infection were treated with ritipenem acoxil. According to thecriteria of the Japanese UTI Committee, the overall clinical efficacy rate was 100%(2/2) for AUC and 85.7%(24/28) for chronic complicated UTI. Bacteriologically, 28 of 32 strains (87.5%) wereeradicated. 3) Side effects: No side effects were observed. Abnormal laboratory findings, however, wereobserved in 2 cases, one with slight elevations of GOT and GPT and the other with decreases in RBC, Hb and Ht. © 1995, Japanese Society of Chemotherapy. All rights reserved.

DOI： 10.11250/chemotherapy1995.43.Supplement3_256

A study on the combined use of azithromycin and ofloxacin in refractory complicated urinary tract infection Reviewed

Noriaki Ono, Toyohiko Watanabe, Tadasu Takenaka, Koushi Sakuramoto, Toshihide Hayashi, Kazuhiro Hata, Hiromi Kumon, Hiroyuki Ohmori, Katsuyoshi Kondo, Teruhisa Ohashi, Katsuichi Namba, Teruaki Akaeda, Yasuhiro Katayama, Toshihiko Asahi, Masaya Tsugawa, Syunji Hayata, Yoshitsugu Nasu, Kazuhisa Takeda

Japanese Journal of Chemotherapy 43 ( 2 ) 222 - 230 1995

Language：English Publishing type：Research paper (scientific journal)

The efficacy and safety of combined therapy including azithromycin (AZM) and ofloxacin (OFLX) and single therapy with OFLX were compared in patients with rafractory complicated urinary tract infection (UTI) caused by catheters, to assess these methods of treating biofilm infection of the urinary tract. The subjects were patients with UTI who were treated with urethral catheter (including cystostomy). Seven days before the start of administration, the indwelling catheter was changed, and the course was observed without administration of any antimicrobial drug. Patients were registered at the time of this observation. The combined therapy group was given AZM at a single daily dose of 500 mg for 3 days and OFLX at a dose of 200 mg three times a day for 7 days. The single therapy group was given OFLX at a dose of 200 mg three times a day for 7 days. Eight days after the start of administration, the catheter was changed again. Urinary sediment and culture, and clinical tests were performed before and after the administration of drugs, and the surface of the catheter was observed by electron microscopy. Fifteen of the 37 patients were assigned to the combined therapy group and 17 to the single therapy group. The efficacy rates were 66.7% and 47.1% in the respective groups, as evaluated by the attending doctor. According to the criteria of the Japanease UTI committee, overall clinical efficacy was 60.0% in the combined therapy group and 41.2% in the single therapy group. The urine became negative for bacteria in 53.3% of the patients in the combined therapy group and 35.3% of those in the single therapy group. The bacteriological eradication rate was 91.2% in the combined therapy group and 68.8% in the single therapy group. There were no associated side effects or abnormal changes in clinical laboratory test values except for discomfort in the stomach of one patient in the combined therapy group. The inhibitory effect on biofilm formation as determined by electron microscopy tended to be superior in the combined therapy group. These results suggest that combined therapy with AZM and OFLX is an effective method of treating refractory complicated UTI in patients with a catheter. © 1995, Japanese Society of Chemotherapy. All rights reserved. © 1995, Japanese Society of Chemotherapy. All rights reserved.

DOI： 10.11250/chemotherapy1995.43.222

Basic and clinical evaluation of carindacillin for complicated urinary tract infection caused by Pseudomonas aeruginosa Reviewed

Toyohiko Watanabe, Tadasu Takenaka, Koushi Sakuramoto, Kouichi Monden, Toshihide Hayashi, Kazuhiro Hata, Noriaki Ono, Masaya Tsugawa, Hiromi Kumon, Hiroyuki Ohmori, Katsuyoshi Kondo, Syunji Hayata, Yoshitsugu Nasu, Teruaki Akaeda, Yasuhiro Katayama

Japanese Journal of Chemotherapy 43 ( 1 ) 89 - 95 1995

Language：English Publishing type：Research paper (scientific journal)

We evaluated the antibacterial activity and efficacy of carindacillin (CIPC), a synthetic penicillin, in the urological field. 1) Antimicrobial activities: Statistical studies were performed on Psudomonas aeruginosa isolated from patients with urinary tract infection from 1983 to 1991. Antimicrobial activities of new quinolones against these strains were annually reduced both in Muller-Hinton broth (MHB) and in artifical urine (AU). Antimicrobial activities of new quinolones in AU were more reduced than those in MHB, but the antimicrobial activities of CIPC were less reduced in both MHB and AU than those of the new quinolones. It was considered that the antimicrobial activities of the new quinolones were reduced due to low pH and high concentrations of magnesium and calcium in AU. 2) Clinical efficacy: According to the criteria of the Japanese UTI Committee, the overall clinical efficacy rate was 61.9% (13/21). Bacteriologically, 21 of 34 strains (61.8%) isolated were eradicated. The eradication rate for P. aeruginosa was 57.1% (12/21). 3) Side effects: No clinical side effects or abnormal laboratory changes were observed. Based on the above results, CIPC might be useful in the treatment of urinary tract infection caused by P. aeruginosa. © 1995, Japanese Society of Chemotherapy. All rights reserved.

DOI： 10.11250/chemotherapy1995.43.89

Basic and clinical studies on cefluprenam in urinary tract infections Reviewed

Koushi Sakuramoto, Ryuji Fujita, Toyohiko Watanabe, Tadasu Takenaka, Kouichi Monden, Toshihide Hayashi, Kazuhiro Hata, Noriaki Ono, Yoshitsugu Nasu, Masaya Tsugawa, Hiromi Kumon, Hiroyuki Ohmori, Katsuichi Nanba, Yasuhiro Katayama, Teruaki Akaeda

Japanese Journal of Chemotherapy 43 127 - 133 1995

Language：English Publishing type：Research paper (scientific journal)

We studied the antibacterial activity and clinical efficacy of cefluprenam (CFLP), a new injectable cephalosporin antibiotic, in urinary tract infections. 1) Antibacterial activity: The MICs of CFLP were measured against 210 clinical isolates of 14 species from urinary tract infections and compared with those of ceftazidime (CAZ), cefoperazone (CPZ), latamoxef (LMOX) and imipenem (IPM). In general, the antibacterial activity of CFLP was superior to those of other compared cephems except for IPM, but slightly inferior to that of IPM. 2) Clinical efficacy: Fourteen patients with complicated urinary tract infection were treated once or twice a day with 0.5g or 1.0g of CFLP. Out of 14, 12 cases were evaluated according to the criteria of the apanese UTI Committee. The overall clinical efficacy rate was 66.7%(8/12). Bacteriologically, 17 of 20 strains (85%) were eradicated. 3) Side effect: No clinical side effects and no abnormal laboratory changes were observed in any cases. © 1995, Japanese Society of Chemotherapy. All rights reserved.

DOI： 10.11250/chemotherapy1995.43.Supplement4_127

液胞型H^+-ATPaseのE.coliの膀胱付着に及ぼす影響について

那須良次, 渡辺豊彦, 櫻本耕司, 小野憲昭, 津川昌也, 公文裕巳, 大森弘之, 友近健一, 篠田純男

日本泌尿器科学会雑誌 86 ( 3 ) 791 - 791 1995

共焦点レーザー走査顕微鏡による細菌バイオフィルムの観察

渡辺豊彦, 小野憲昭, 公文裕巳, 大森弘之, 友近健一, 小熊恵二

日本泌尿器科学会雑誌 86 ( 1 ) 167 - 167 1995

前立腺肥大症に対するVLAPの臨床的検討 : 長期成績と合併症について

那須保友, 渡辺豊彦, 公文裕巳, 大森弘之, 入江伸, 西村元一, 金重哲三

日本泌尿器科学会雑誌 86 ( 1 ) 239 - 239 1995

泌尿器科領域感染症におけるbiapenemの基礎的・臨床的検討

渡辺豊彦, 竹中皇, 林俊秀

日本化学療法学会雑誌 42 ( Suppl.4 ) 486 - 496 1994.12

Language：Japanese Publisher：(公社)日本化学療法学会

1)尿路感染症分離株14菌種210株に対するBIPMのMICを測定し,imipenem (IPM), ceftazidime (CAZ), latamoxef (LMOX)およびcefoperazone (CPZ)と比べた。全体的に見ると本剤の抗菌力は,IPMとほぼ同等,CAZ, LMOXおよびCPZより3〜4管程度優れていた。2)複雑性尿路感染症30例を対象に,本剤1回150〜450mgを1日2回,4〜8日間投与した。評価可能であった23例の総合臨床効果は著効7例,有効10例,無効6例であった。細菌学的効果では35株中,消失30株,存続5株であった。急性前立腺炎の1例は主治医判定で有効であった。副作用および臨床検査値異常変動はなかった

ニューキノロン薬のPseudomonas aeruginosaに対する抗菌力の年次推移と尿中抗菌力について

渡辺豊彦, 竹中皇, 桜本耕司

緑膿菌感染症研究会講演記録 28回 135 - 141 1994.11

Language：Japanese Publisher：緑膿菌感染症研究会

MIC測定用broth中での緑膿菌に対する抗菌力は,今回検討したニューキノロン薬すべてにおいて年次的に耐性化が認められた。また,人工尿中における抗菌力は,多くのニューキノロン薬においてMIC測定用brothと比較して3管程度低下しており,年次的にも耐性化傾向が認められた。MIC測定用brothと人工尿の組成を比較したところpH, Mg2+濃度,Ca2+濃度に相違が認められ,人工尿のpHがMIC測定用brothに比し低値であること,また,Mg2+, Ca2+など2価の陽イオン濃度が高値であることが尿中MICの上昇に関与している

　 PREV - NEXT 　

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22